Search results
Results from the WOW.Com Content Network
An anti-sense oligonucleotide (ASO) is a short piece of synthetic DNA complementary to the sequence of a variable target DNA. It acts as a probe for the presence of the target in a Southern blot assay or, more commonly, in the simpler dot blot assay.
Anti-streptolysin O (ASO or ASLO) is the antibody made against streptolysin O, an immunogenic, oxygen-labile streptococcal hemolytic exotoxin produced by most strains of group A and many strains of groups C and G Streptococcus bacteria. The "O" in the name stands for oxygen-labile; the other related toxin being oxygen-stable streptolysin-S.
Antisense therapy is a form of treatment that uses antisense oligonucleotides (ASOs) to target messenger RNA (mRNA). ASOs are capable of altering mRNA expression through a variety of mechanisms, including ribonuclease H mediated decay of the pre-mRNA, direct steric blockage, and exon content modulation through splicing site binding on pre-mRNA. [1]
The basic principles of SNP array are the same as the DNA microarray. These are the convergence of DNA hybridization, fluorescence microscopy, and solid surface DNA capture. The three mandatory components of the SNP arrays are: [3] An array containing immobilized allele-specific oligonucleotide (ASO) probes.
Seoul's diplomats further noted that the North's "denuclearization," a term meaning removal of its nuclear weapons, "has been a principle consistently upheld by South Korea, the United States and ...
Post-streptococcus glomerulonephritis is more often associated with group A strep skin infection than it is with strep pharyngitis, so in a patient with suspected post-strep glomerulonephritis with a negative ASO titer, one can then obtain anti-DNase-B titers which are more sensitive for group A strep and for its various strains.
Whether you're a recent fan or you've been wearing them since the early 2000s, UGGs have proven one thing: they can stand the test of time. A mish-mosh of trendy and classic styles, UGG is not ...
Ratner anticipates AKTIV will be ready to test in sheep or pigs in a year or two and, if all goes to plan, in humans by 2026 or 2027. Funding remains a perpetual issue, and researchers are wary of ...